Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III recombinant 9-valent HPV vaccine study in healthy females
ChiCTR2100046752Phase 3Recruiting
- Sponsor
- Henan Provincial Center for Disease Control and Prevention
- Start
- Jun 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by Henan Provincial Center for Disease Control and Prevention. Primary endpoints: Gynecological examination, High-risk HPV-DNA typing test and 4 more. Started Jun 2021; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100046752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046752.